Back to search

BIA-Brukerstyrt innovasjonsarena

A novel antimicrobial agent for topical treatment of challenging infections caused by drug-resistant bacteria.

Awarded: NOK 8.8 mill.

Project Number:


Project Period:

2006 - 2009

Funding received from:


"Once life-saving medicines are increasingly having as little effect as a sugar pill. Since 1970, no new classes of antibacterials have been developed to combat infectious diseases. Microbial resistance to treatment could bring the world back to a pre-an tibiotic age." WHO Report 2000: Overcoming Antimicrobial Resistance Antibiotic resistance is rapidly becoming a threat to our capacity to treat common infectious diseases. Antimicrobial peptides with their unique and rapid mode of action against multidr ug resistant bacteria are much less prone to resistance development than conventional antibiotics, but despite these very attractive features antimicrobial peptides have yet failed to reach the clinic. Lytix has developed a broad technology platform enabl ing the medicinal chemistry modification of naturally occurring peptides into promising drug candidates. Lytix specialises in developing products into early clinical phases for use against resistant bacteria and cancer. Our preclinical verification studie s (supported by MEDKAP) have shown that all of our lead candidate molecules tested showed at least similar, and often superior results, than antibiotics in clinical use today. The worldwide yearly sales of antimicrobials (anti-bacteria and -fungi) are e stimated at US$25 billion in 2002 (IMS World Health Report). The potential economic value generated by Lytix if successful in licensing product rights to an international partner is considerable. The Board of Directors, managers and collaborators have con siderable industrial expertise and networks that will ensure a successful commercialisation process. Comprehensive plans for project management, financing, communication and partnering have been developed. Lytix has decided, based on the positive verific ation studies and evaluation by international experts, to initiate preclinical and early phase clinical development of LTX-100, a topical agent for treatment of MRSA and GAS infections.

Funding scheme:

BIA-Brukerstyrt innovasjonsarena